Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Rtw Biotech Share Price
  4. Rtw Biotech Share Regulatory News
  5. Director Declaration

Pin to quick picksRtw Biotech Regulatory News (RTW)

Rtw Biotech Information

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.19
Ask:
2.21
Spread: 0.02 (0.913%)
Market Cap: $714.60m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Director Declaration

31 May 2024 12:00

RNS Number : 6721Q
RTW Biotech Opportunities Ltd
31 May 2024
 

LEI: 549300Q7EXQQH6KF7Z84

31 May 2024

RTW Biotech Opportunities Ltd (the "Company")

Director Declaration

In accordance with LR 9.6.14, the Company announces that Paul Le Page, a non-executive director of the Company, will join the board of Sequoia Economic Infrastructure Income Fund Limited, as a non-executive director with effect from 7 June 2024.

For Further Information:

 

RTW Investments, LP

+44 (0)20 7959 6361

biotechopportunities@rtwfunds.com

Woody Stileman, Managing Director

Krisha McCune, Director, Investor Relations

 

 

 

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNBGGDURGXDGSB
12345678910
Date   Source Headline
13th Feb 20267:00 amRNSMonthly Valuation Update and Factsheet
23rd Jan 20267:00 amRNSCorxel completes $287 million Series D-1 financing
22nd Jan 202610:00 amRNSDirector/PDMR Shareholding
21st Jan 20267:00 amRNSGSK to acquire RAPT Therapeutics
16th Jan 20267:00 amRNSBoston Scientific to acquire Penumbra
15th Jan 20267:00 amRNSMonthly Valuation Update and Factsheet
12th Jan 20267:00 amRNSAktis announces $318 million IPO
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
18th Dec 20257:00 amRNSNew investment in Yarrow Bioscience
12th Dec 20257:00 amRNSMonthly Valuation Update and Factsheet
10th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSInclusion in FTSE 250 Index
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20256:00 pmRNSSpectris
1st Dec 20257:00 amRNSTotal Voting Rights
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20252:30 pmRNSTransaction in Own Shares
25th Nov 202512:00 pmRNSRetail Investor Webinar
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:00 amRNSMonthly Valuation Update and Factsheet
7th Nov 20257:00 amRNSEvommune announces $150 million IPO
5th Nov 202510:00 amRNSHolding(s) in Company
3rd Nov 20259:33 amRNSTotal Voting Rights
31st Oct 20257:00 amRNSRoyalty Funding Agreement with Savara Inc.
29th Oct 20257:00 amRNSTransaction in Own Shares
27th Oct 20257:00 amRNSNovartis to acquire Avidity Biosciences
20th Oct 20257:00 amRNSCapital Allocation Plan based on M&A successes
15th Oct 20257:00 amRNSKailera Therapeutics announces Series B financing
14th Oct 20257:00 amRNSMonthly Valuation Update and Factsheet
10th Oct 20257:00 amRNSNovo Nordisk to acquire Akero Therapeutics
1st Oct 20257:00 amRNSTotal Voting Rights
30th Sep 20257:01 amRNSTransaction in Own Shares
30th Sep 20257:00 amRNSGenmab to acquire Merus
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20257:00 amRNSTransaction in Own Shares
25th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSTransaction in Own Shares
23rd Sep 20257:01 amRNSTransaction in Own Shares
23rd Sep 20257:00 amRNSBiogen to acquire Alcyone Therapeutics
15th Sep 20257:00 amRNSMonthly Valuation Update and Factsheet
11th Sep 20257:00 amRNSHalf-year Report
5th Sep 20257:00 amRNSInclusion in FTSE All-Share Index
1st Sep 20257:00 amRNSTotal Voting Rights
22nd Aug 20257:00 amRNSTransaction in Own Shares
19th Aug 20257:01 amRNSNotice of Interim Results
19th Aug 20257:00 amRNSStrategic Funding Agreement with Aquestive
15th Aug 20257:00 amRNSTransaction in Own Shares
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
DG81
Citi Fun 27
LSE
0.00%
DQ45
Citi Fun 27
LSE
0.00%
FF08
Sg Issuer 33
LSE
0.00%
UB57
Nationwde 29
LSE
0.00%
WP05
Barclays 31
LSE
0.00%
Trending
CPX
CAP-XX
LSE
-1.82%